Logo image of GNLX

GENELUX CORP (GNLX) Stock Fundamental Analysis

NASDAQ:GNLX - Nasdaq - US36870H1032 - Common Stock - Currency: USD

3.47  -0.13 (-3.61%)

Fundamental Rating

3

Taking everything into account, GNLX scores 3 out of 10 in our fundamental rating. GNLX was compared to 556 industry peers in the Biotechnology industry. While GNLX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, GNLX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GNLX had negative earnings in the past year.
In the past year GNLX has reported a negative cash flow from operations.
GNLX had negative earnings in each of the past 5 years.
GNLX had a negative operating cash flow in each of the past 5 years.
GNLX Yearly Net Income VS EBIT VS OCF VS FCFGNLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of GNLX (-76.62%) is worse than 67.99% of its industry peers.
With a Return On Equity value of -100.08%, GNLX perfoms like the industry average, outperforming 45.68% of the companies in the same industry.
Industry RankSector Rank
ROA -76.62%
ROE -100.08%
ROIC N/A
ROA(3y)-93.9%
ROA(5y)-116.11%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GNLX Yearly ROA, ROE, ROICGNLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

GNLX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GNLX Yearly Profit, Operating, Gross MarginsGNLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100K -200K -300K

More info and screens

6

2. Health

2.1 Basic Checks

GNLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GNLX has more shares outstanding
The number of shares outstanding for GNLX has been increased compared to 5 years ago.
There is no outstanding debt for GNLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GNLX Yearly Shares OutstandingGNLX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
GNLX Yearly Total Debt VS Total AssetsGNLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

GNLX has an Altman-Z score of -2.19. This is a bad value and indicates that GNLX is not financially healthy and even has some risk of bankruptcy.
GNLX's Altman-Z score of -2.19 is in line compared to the rest of the industry. GNLX outperforms 51.62% of its industry peers.
There is no outstanding debt for GNLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.19
ROIC/WACCN/A
WACC9.75%
GNLX Yearly LT Debt VS Equity VS FCFGNLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

GNLX has a Current Ratio of 4.67. This indicates that GNLX is financially healthy and has no problem in meeting its short term obligations.
GNLX has a Current ratio (4.67) which is in line with its industry peers.
A Quick Ratio of 4.67 indicates that GNLX has no problem at all paying its short term obligations.
The Quick ratio of GNLX (4.67) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.67
Quick Ratio 4.67
GNLX Yearly Current Assets VS Current LiabilitesGNLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.28% over the past year.
GNLX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -95.29%.
EPS 1Y (TTM)9.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.59%
Revenue 1Y (TTM)-95.29%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, GNLX will show a very strong growth in Earnings Per Share. The EPS will grow by 34.92% on average per year.
Based on estimates for the next years, GNLX will show a very strong growth in Revenue. The Revenue will grow by 782.52% on average per year.
EPS Next Y1.4%
EPS Next 2Y-3.21%
EPS Next 3Y10.67%
EPS Next 5Y34.92%
Revenue Next Year-100%
Revenue Next 2Y2473.91%
Revenue Next 3Y2015.23%
Revenue Next 5Y782.52%

3.3 Evolution

GNLX Yearly Revenue VS EstimatesGNLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
GNLX Yearly EPS VS EstimatesGNLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GNLX. In the last year negative earnings were reported.
Also next year GNLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNLX Price Earnings VS Forward Price EarningsGNLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNLX Per share dataGNLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.21%
EPS Next 3Y10.67%

More info and screens

0

5. Dividend

5.1 Amount

GNLX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENELUX CORP

NASDAQ:GNLX (7/24/2025, 8:00:01 PM)

3.47

-0.13 (-3.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners19.38%
Inst Owner Change4.77%
Ins Owners11.6%
Ins Owner Change-2.15%
Market Cap130.92M
Analysts83.64
Price Target17.95 (417.29%)
Short Float %7.02%
Short Ratio15.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.29%
Min EPS beat(2)-39.67%
Max EPS beat(2)15.1%
EPS beat(4)2
Avg EPS beat(4)-9.47%
Min EPS beat(4)-39.67%
Max EPS beat(4)15.1%
EPS beat(8)2
Avg EPS beat(8)-18.04%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.62%
EPS NY rev (1m)0%
EPS NY rev (3m)8.8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16365.39
P/FCF N/A
P/OCF N/A
P/B 4.39
P/tB 4.39
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0
BVpS0.79
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.62%
ROE -100.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-93.9%
ROA(5y)-116.11%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 181.43%
Cap/Sales 4762.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.67
Quick Ratio 4.67
Altman-Z -2.19
F-Score4
WACC9.75%
ROIC/WACCN/A
Cap/Depr(3y)125.54%
Cap/Depr(5y)76.05%
Cap/Sales(3y)1788.63%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.59%
EPS Next Y1.4%
EPS Next 2Y-3.21%
EPS Next 3Y10.67%
EPS Next 5Y34.92%
Revenue 1Y (TTM)-95.29%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y2473.91%
Revenue Next 3Y2015.23%
Revenue Next 5Y782.52%
EBIT growth 1Y-31.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year24.42%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-103.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-102.99%
OCF growth 3YN/A
OCF growth 5YN/A